Ardelyx reports $378 million in 2025 revenue, projects growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
January 8, 2026 8:30 AM ESTCompany achieved significant commercial progress in 2025, generating approximately $378 million in product revenue1Â
IBSRELA achieved $274 million in revenue in 2025, representing 73% growth vs. 20241
IBSRELA expected to achieve $410-430 million in revenue in 2026
IBSRELA revenue expected to reach $1 billion in 2029
WALTHAM, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today provided its preliminary... More
